Fingerprint
Dive into the research topics of 'Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically